ArticleFrontiers in medicine2026
Integrative serum proteomic and metabolomic profiling in ovarian endometrioma: an exploratory multi-omics study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian endometrioma (OEM) is a common manifestation of endometriosis and is associated with both local lesions and systemic alterations. While immune dysregulation and metabolic disturbances have been individually reported in endometriosis, whether these changes are coordinated at the circulating molecular level in OEM remains unclear. Methods: We performed an exploratory integrative analysis of serum proteomic and untargeted metabolomic profiles in women with OEM and healthy controls. Differential analyses were conducted for each omics layer, followed by cross-omics integration to assess pathway-level relationships between molecular alterations. Selected platelet-associated proteins were further evaluated by enzyme-linked immunosorbent assay (ELISA) in a small independent cohort. Results: Serum proteomics profiling showed predominant alterations in immune-related and extracellular processes, whereas metabolomic analysis revealed changes mainly involving lipid metabolism, amino acid metabolism, and redox-related pathways. Cross-omics integration suggested pathway-level correspondence between the two omics layers, particularly in carbohydrate metabolism, nucleotide metabolism, lipid remodeling, and antioxidant defense. Among platelet-associated proteins, pro-platelet basic protein (PPBP/CXCL7) showed higher levels in OEM in both proteomic profiling and ELISA validation, while MMRN1 and PDGFA showed concordant but non-significant increases in the ELISA cohort. Conclusion: These findings suggest that OEM is associated with concurrent immune-related and metabolic alterations detectable in the circulation. Integrative multi-omics analysis provides exploratory evidence for pathway-level correspondence between proteomic and metabolomic alterations in OEM and provides limited independent support for a platelet-associated circulating signal, with PPBP showing the most consistent validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.